Plaque-Targeted Anti-Inflammatory Therapy

Inflammation is the major driver of heart attacks for patients with coronary artery disease. Using a new therapeutic approach, we are addressing the problem in a highly specific manner to maximize benefit to patients while also minimizing the risks.

Pale pink icon of a heart with a heartbeat pattern running through the middle.

Coronary Artery Disease (CAD) is the #1 cause of death worldwide.

CAD is the leading cause of death worldwide.  It is a condition characterized by the buildup of plaque in the arteries that supply blood to the heart muscle (a condition called atherosclerosis). This build-up causes inflammation, which often goes untreated, and ultimately leads to an acute coronary syndrome (ACS) event such as a heart attack or unstable angina.

0M
Patients in the US living with CAD
0k
Deaths in the US from CAD each year
0K
US hospitalizations for ACS annually

Coronary Inflammation causes heart attacks

For many decades, cardiologists have known that inflammation plays a key role in the development of CAD and causes heart attacks. Systemic treatments for inflammation can help, but also come with other potential serious risks and side effects.

Abcentra’s Innovative Solution:

Treat Vascular Inflammation Locally

Abcentra’s targeted approach provides the ability to intervene with precision, which has promise to maximize the benefit to patients while minimizing the risks.

Orticumab is a first-in-class monoclonal antibody against oxidized LDL that targets vascular inflammation locally.

White quotation marks

Our mission to combat arterial inflammation isn’t just about developing a drug, it is about rewriting the narrative around cardiovascular health. We believe in a future where the message of every heartbeat is vitality – not vulnerability.

Chris Farina – CEO, Abcentra

Join our team at an event near you.

You can find our team at cardiovascular events around the globe.
Attend some of these events and use the form on our contact page to schedule a meeting.